相关实验视频
Updated: Sep 11, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.6K
在原发性阿尔多斯特主义中,阿尔多斯特抑制试验的不一致性和缺陷
Cheng-Hsuan Tsai1,2,3, Stefanie Parisien-La Salle1,4, Jenifer M Brown1,5
1Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, United States.
European journal of endocrinology
|August 12, 2025
概括
像盐水抑制试验 (SST) 和卡普托普利挑战试验 (CCT) 这样的阿尔多斯特抑制试验显示出诊断初级阿尔多斯特主义 (PA) 和预测单边疾病的显著不一致性和不准确性.
科学领域:
- 内分泌学 在内分泌学.
- 临床诊断 临床诊断 临床诊断
- 医学研究 医学研究
背景情况:
- 原发性阿尔多斯特隆症 (PA) 诊断传统上依赖于盐水抑制试验 (SST) 和卡波普里尔挑战试验 (CCT).
- 目前的指导方针表明,这些测试可以预测单方面PA,指导治疗决策.
- 这项研究批判性地评估了SST和CCT的诊断性能.
研究的目的:
- 评估SST和CCT的诊断准确性和一致性,在患有高概率PA的患者中.
- 确定这些测试在预测单边PA和手术结果方面的可靠性.
- 为了确定当前的阿尔多激素抑制测试协议的局限性.
主要方法:
- 追溯分析了531名怀疑患有PA的患者,这些患者接受了SST和CCT.
- 对上腺侧面化和手术治疗的临床判断进行测试结果的评估.
- 分析测试一致性,假阴性率和单边上腺切除术后的结果.
主要成果:
- 在SST和CCT之间,PA诊断率差异很大 (47.8%97.2%).
- 在SST和CCT结果之间观察到显著的不一致性 (10.9%51.6%).
- 即使在明显的PA病例中,也发现了低于最佳的阳性率和持续的不一致性;观察到显著的虚假阴性率 (高达5.1%).
结论:
- 已建立的阿尔多抑制试验 (SST,CCT) 显示出大量的不一致性和假阴性率.
- 这些测试对于准确诊断PA和预测高风险患者的横向化是不可靠的.
- 目前的阿尔多激素抑制测试缺乏足够的准确性来诊断和亚型PA.
相关概念视频
Adrenal Gland Disorders
1.8K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.8K
Antihypertensive Drugs: Potassium-Sparing Diuretics
768
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
768
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508
Antihypertensive Drugs: Direct Renin Inhibitors
823
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
823
Heart Failure Drugs: Diuretics
484
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
484
Hormonal Regulation
33.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.7K

